Nanobiotix S.A. to Post FY2025 Earnings of $1.07 Per Share, Leerink Partnrs Forecasts (NASDAQ:NBTX)

Nanobiotix S.A. (NASDAQ:NBTX) – Investment analysts at Leerink Partnrs boosted their FY2025 earnings estimates for shares of Nanobiotix in a research report issued to clients and investors on Thursday, April 25th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of $1.07 per share for the year, up from their prior estimate of $1.06. The consensus estimate for Nanobiotix’s current full-year earnings is ($0.86) per share.

Nanobiotix Price Performance

Nanobiotix stock opened at $5.74 on Monday. The company’s 50 day simple moving average is $6.29 and its 200-day simple moving average is $6.55. Nanobiotix has a 1 year low of $1.75 and a 1 year high of $11.00.

Institutional Investors Weigh In On Nanobiotix

A hedge fund recently raised its stake in Nanobiotix stock. Baillie Gifford & Co. increased its holdings in shares of Nanobiotix S.A. (NASDAQ:NBTX) by 48.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,869,030 shares of the company’s stock after buying an additional 932,835 shares during the period. Baillie Gifford & Co. owned about 6.09% of Nanobiotix worth $20,887,000 at the end of the most recent quarter. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.